



GEORGIA DEPARTMENT
OF COMMUNITY HEALTH

Georgia Department of Community Health

DRUG UTILIZATION REVIEW BOARD MEETING

Department of Community Health

January 21, 2026



**DRUG UTILIZATION REVIEW BOARD MEETING
AGENDA**

*2 Martin Luther King Jr. Drive, S.E.
Atlanta, Georgia 30334*

*Department of Community Health Board Room - Room 470-A
East Tower, Balcony Level*

**Wednesday, January 21, 2026
10:00 a.m. to 2:00 p.m.**

CALL TO ORDER	<i>Osgood (Drew) A. Miller, R.Ph., Vice-Chair</i>
MINUTES FROM PREVIOUS MEETING	<i>Chair</i>
EXTERNAL COMMENTS SESSION	<i>Chair</i>
CLINICAL REVIEWS	<i>Mary-Beth Plum, PharmD, BCACP, NorthStar Jerel Applewhite, PharmD, MBA, NorthStar Emily Baker, PharmD, BCPS, NorthStar</i>
<ul style="list-style-type: none"> ➤ New Drugs <ul style="list-style-type: none"> ● Leqselvi ● Tryptyr ● Zelsuvmi 	
ADJOURNMENT OF OPEN SESSION	<i>Chair</i>
EXECUTIVE SESSION	<i>Chad Nicholson, PharmD, Prime Therapeutics Afzal Mistry, PharmD, Prime Therapeutics Nina Bandali, PharmD, Prime Therapeutics</i>
RECONVENING OF OPEN SESSION	<i>Chair</i>
BOARD’S RECOMMENDATIONS AND VOTES	<i>Chair</i>
FUTURE AGENDA ITEMS	<i>Chair</i>
ADJOURNMENT OF MEETING	<i>Chair</i>

Department of Community Health Drug Utilization Review Board (DURB) MINUTES Wednesday, October 15, 2025

MEMBERS PRESENT

Osgood (Drew) A. Miller, R.Ph., Vice-Chair
Alton Condra, III, R.Ph.
M. Celeste Fowler, Pharm.D., HCMBA
Glenda Wrenn Gordon, M.D., MSHP, FAPA
Burton L. Lesnick, M.D., FAAP
Robyn Lorys, Pharm.D.
Brent L. Rollins, R.Ph., Ph.D.
J. Russell (Rusty) May, Pharm.D.
Matthew Perri, Pharm.D., R.Ph., Ph.D.
Danny A. Toth, R.Ph.
Suzanne Walton, Pharm.D., BCPS, BCOP

MEMBERS ABSENT

Gurinder Doad, M.D., Ph.D., Chair
Doug Collins, M.D.
Torey Jones, Pharm.D.

Staff

Peter D'Alba, Pharm.D., Deputy Executive Director, Chief Pharmacy Officer, Pharmacy Services
Gilletta Gray, R.Ph., Clinical Manager, Pharmacy Services
Ashlee Henry, MSHI, Pharmacy Operations Supervisor
Ashley Bellino, Pharmacy Operations Specialist, Pharmacy Services
Rose Duncan, MBA, Operations Analyst-Drug Rebate Program, Pharmacy Services
Lori Garner, MHS, MBA, R.Ph., Pharmacist, SHBP
Sydney DeNeve, Pharm.D., Pharmacist, SHBP

NorthStar HealthCare Consulting

Emily Baker, Pharm.D., BCPS, MHA, MBA, President
Chad Nicholson, Pharm.D., Clinical Programs Director
Mary-Beth Plum, Pharm.D., BCACP, Clinical Pharmacist

OptumRx

Mark Hall, MBA, PMP, Assoc. Director, Government and Public Sector Markets
Talmahjia "Tami" Sweat, Pharm.D., Clinical Consulting

Magellan Rx Management/Prime Therapeutics

Afzal "Fez" Mistry, Pharm.D., Pharmacist Account Manager

Care Management Organizations

Turkesia Robertson-Jones, Pharm.D., CareSource
Cassandra Tancil, Pharm.D., BCPS, Amerigroup

Pharmacy Students/Residents

Sarah Dubin, Pharm.D. candidate (Augusta University)

**Department of Community Health
Drug Utilization Review Board (DURB)**

MINUTES

Wednesday, October 15, 2025

Alexis Grady Pharm.D. candidate (Augusta University)

Nghi Nguyen, Pharm.D. resident (Augusta University)

Call to Order

The Drug Utilization Review Board (DURB/DUR Board/Board) held its fourth meeting for the calendar year on October 15, 2025. The Vice-Chair, Osgood (Drew) A. Miller, R.Ph., called the meeting to order at 10:06am.

Minutes from the Previous Meeting

Vice-Chair Miller asked for corrections or changes to the minutes from the July 15, 2025 meeting. A motion was made (J. Russell (Rusty) May, Pharm.D.) and seconded (Robyn Lorys, Pharm.D.) and carried to approve the minutes as written.

External Comments Session

There were no external comments presented to the Board.

New Drug Reviews

Clinical information for the following new drugs, in the market six months or more, was presented for discussion and recommendations. The complete detailed drug summary is in the New Drugs for Review section of the DUR Board binder.

Therapeutic Class	Drugs	Presenter
Hemophilia Treatment	<i>Qfitlia</i>	Mary-Beth Plum, Pharm.D., BCACP
Oncology, Oral - Other	<i>Romvimza</i>	Mary-Beth Plum, Pharm.D., BCACP
Colony Stimulating Factors	<i>Ryzneuta</i>	Chad Nicholson, Pharm.D.
IgA Nephropathy Agents	<i>Vanrafia</i>	Chad Nicholson, Pharm.D.

The Board discussed the drug information, provided comments, and raised questions on the following:

- Qfitlia – Difficult to assess thrombosis rates among comparative agents because of the way the trials were conducted; all have warning for thrombosis; Dosing-about 67% of patients maintained 2-month dosing, 18% had to go to monthly dosing, and 15% had to come off of therapy due to thrombosis; increase incidence of cholelithiasis/gallbladder disease with monthly dosing.
- Ryzneuta – First trial study looked at 122 women with breast cancer – surprising, ethically, to see trial design was placebo-controlled.

**Department of Community Health
Drug Utilization Review Board (DURB)**

MINUTES

Wednesday, October 15, 2025

- Vanrafia – revisit criteria with new guidance on dual therapy and glucocorticoid step with targeted enteric coated budesonide; step of Filspari would be based on cost.

DCH Decisions

DCH Decisions from the July 2025 DUR Board meeting were provided in the DCH Decision section of the DUR Board binder.

Upcoming Meetings

The following upcoming meetings were announced:

- Drug Utilization Review Board
2 Martin Luther King Jr. Drive, SE
East Tower
Atlanta, Georgia 30334

Wednesday, January 21, 2026:	10:00am – 2:00pm
Wednesday, April 15, 2026:	10:00am – 2:00pm
Wednesday, July 15, 2026:	10:00am – 2:00pm
Wednesday, October 21, 2026:	10:00am – 2:00pm

Disclosure Forms

Disclosure forms were received and reviewed by the Department for completeness for all Board members attending the meeting.

Adjournment of Open Session

The DUR Board voted to have the Executive Session pursuant to the Open Meetings Act of Georgia Section 50-14-1 – 50-14-6 and pursuant to Federal Law Section 1396R-8B3D. The individuals recorded in attendance with the Board members were from the Department of Community Health, Prime Therapeutics, NorthStar HealthCare Consulting, OptumRx, and pharmacy students. A motion was made by Danny A. Toth, R.Ph. and seconded by Brent L. Rollins, R.Ph., Ph.D. to approve the closed session. There was a unanimous vote approving the closed session. The Vice-Chair, Osgood (Drew) A. Miller, R.Ph., adjourned the open session at approximately 11:21am, at which time members took a break then reconvened for the executive (closed) session.

Executive Session

The Executive Session was held from 11:34am to 11:57am.

Reconvening of Open Session

The DUR Board reconvened for the open session at 12:01pm.

Board's Recommendations to the Department

After all clinical and financial evaluations and discussions, the DUR Board voted and presented the Department with the following recommendations for changes to the Preferred Drug List (PDL) or Physician Administered Drug List (PADL) as noted in Attachment A. All motions and votes are noted in Attachment B.

Future Agenda Items

The were no future agenda items noted.

Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES
Wednesday, October 15, 2025

Conclusion

At the conclusion of the open session and no other business for discussion, Vice-Chair Miller adjourned the meeting at 12:05pm.

THESE MINUTES ARE HEREBY APPROVED AND ADOPTED, THIS THE _____ DAY OF _____, 2025.

Osgood (Drew) A. Miller, R.Ph., Vice-Chair

DRAFT

Drug Utilization Review Board
Motions - Votes - New Drugs
October 15, 2025

New Drug			PDL Status	Motion - Recommendations	Additional Comments	
Hemophilia Treatment		Alhemo (Subcutaneous) Solution	N/A	NP/PA		
		Hypvavzi (Subcutaneous) Solution	N/A	P		
		Qfitlia (Subcutaneous) Solution	N/A	NP/PA		
Board Members - Present <i>(Strike out, when absent)</i>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.			√		
3	Doad, Gurinder J.S., M.D., Ph.D. -Chair					
4	Fowler, M. Celeste, Pharm.D., HCMBA			√		
5	Gordon, Glenda Wrenn, M.D., MSHP, FAPA			√		
6	Jones, Torey, Pharm.D.					
7	Lesnick, Burton, M.D., FAAP	√		√		
8	Lorys, Robyn, Pharm.D.			√		
9	May, J. Russell (Rusty), Pharm.D.			√		
10	Miller, Osgood (Drew) A., R.Ph. -Vice-Chair					
11	Perri, Matthew, R.Ph., Pharm.D., Ph.D.			√		
12	Rollins, Brent L., R.Ph., Ph.D.			√		
13	Toth, Danny, R.Ph.		√	√		
14	Walton, Suzanne, Pharm.D., BCPS, BCOP			√		
			TOTAL	10	0	0
New Drug		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Oncology, Oral - Other		Romvimza (Oral) Capsules	N/A	P/PA		
		Turalio (Oral) Capsules	P/PA	NP/PA		
Board Members - Present <i>(Strike out, when absent)</i>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.			√		
3	Doad, Gurinder J.S., M.D., Ph.D. -Chair					
4	Fowler, M. Celeste, Pharm.D., HCMBA			√		
5	Gordon, Glenda Wrenn, M.D., MSHP, FAPA			√		
6	Jones, Torey, Pharm.D.					
7	Lesnick, Burton, M.D., FAAP			√		
8	Lorys, Robyn, Pharm.D.	√		√		
9	May, J. Russell (Rusty), Pharm.D.			√		
10	Miller, Osgood (Drew) A., R.Ph. -Vice-Chair					
11	Perri, Matthew, R.Ph., Pharm.D., Ph.D.			√		
12	Rollins, Brent L., R.Ph., Ph.D.			√		
13	Toth, Danny, R.Ph.			√		
14	Walton, Suzanne, Pharm.D., BCPS, BCOP		√	√		
			TOTAL	10	0	0
New Drug		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Colony Stimulating Factors		Ryzneuta (Subcutaneous) Solution	N/A	NP/PA (PDL and PADL)		
Board Members - Present <i>(Strike out, when absent)</i>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)

Drug Utilization Review Board
Motions - Votes - New Drugs
October 15, 2025

1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.			√		
3	Doad, Gurinder J.S., M.D., Ph.D. -Chair					
4	Fowler, M. Celeste, Pharm.D., HCMBA			√		
5	Gordon, Glenda Wrenn, M.D., MSHP, FAPA			√		
6	Jones, Torey, Pharm.D.					
7	Lesnick, Burton, M.D., FAAP			√		
8	Lorys, Robyn, Pharm.D.		√	√		
9	May, J. Russell (Rusty), Pharm.D.	√		√		
10	Miller,Osgood (Drew) A., R.Ph.-Vice-Chair					
11	Perri, Matthew, R.Ph., Pharm.D., Ph.D.			√		
12	Rollins, Brent L., R.Ph., Ph.D.			√		
13	Toth, Danny, R.Ph.			√		
14	Walton, Suzanne, Pharm.D., BCPS, BCOP			√		
				TOTAL	10	0
				0	0	
New Drug		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Immunoglobulin A Nephropathy (IgAN) Agents		Vanrafia (Oral) Tablet	N/A	P/PA		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
<i>(Strike out, when absent)</i>				YES (v)	NO (v)	ABSTAIN (v)
1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.			√		
3	Doad, Gurinder J.S., M.D., Ph.D. -Chair					
4	Fowler, M. Celeste, Pharm.D., HCMBA			√		
5	Gordon, Glenda Wrenn, M.D., MSHP, FAPA			√		
6	Jones, Torey, Pharm.D.					
7	Lesnick, Burton, M.D., FAAP	√		√		
8	Lorys, Robyn, Pharm.D.			√		
9	May, J. Russell (Rusty), Pharm.D.			√		
10	Miller,Osgood (Drew) A., R.Ph.-Vice-Chair					
11	Perri, Matthew, R.Ph., Pharm.D., Ph.D.			√		
12	Rollins, Brent L., R.Ph., Ph.D.			√		
13	Toth, Danny, R.Ph.			√		
14	Walton, Suzanne, Pharm.D., BCPS, BCOP		√	√		
				TOTAL	10	0
					0	0

Listed below are Preferred Drug List changes for the State of Georgia Fee-For-Service Medicaid and PeachCare for Kids Programs

Effective January 1, 2026 (see chart below)*

DCH rebate vendor, Prime Therapeutics, has reviewed specific drugs at the October 2025 Drug Utilization Review Board (DURB) meeting and corresponding supplemental rebate offers. The Preferred Drug List (PDL)/Providers' Administered Drug List (PADL) decisions/changes for categories reviewed are outlined below. For a full listing of our PDL, go to www.dch.georgia.gov/pharmacy and select the "Preferred Drug Lists" option; for the PADL, go to <https://www.mmis.georgia.gov/portal/> and select "Provider Information", "Fee Schedule", then "Providers' Administered Drug List."

PREFERRED AGENTS	NON-PREFERRED AGENTS
HEMOPHILIA TREATMENTS	
HYMPAVZI (SUBCUTANEOUS) SOLUTION - PENDING	
	ALHEMO (SUBCUTANEOUS) SOLUTION – PA QFITLIA (SUBCUTANEOUS) SOLUTION – PA
ONCOLOGY, ORAL - OTHER	
ROMVIMZA (ORAL) CAPSULES – PA	TURALIO (ORAL) CAPSULES – PA
COLONY STIMULATING FACTORS	
	RYZNEUTA (SUBCUTANEOUS) SOLUTION* – PA
IMMUNOGLOBULIN A NEPHROPATHY (IgAN) AGENTS	
VANRAFIA (ORAL) TABLET – PA	

*PADL drugs may be subject to a different effective date.



Georgia Department of Community Health (GDCH) Opportunities for Pharmaceutical Manufacturer Input on Clinical Recommendations and Clinical Management Strategies by the Drug Utilization Review Board

Clinical Information and Clinical Management Strategies relevant to the GDCH Medicaid Fee-For-Service program will be presented to the Drug Utilization Review Board (DURB) at each meeting through OptumRx by its vendor NorthStar HealthCare Consulting (NHC). Manufacturer input on new and existing drugs is welcomed and appreciated using these opportunities. **Please note that new drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.**

Ongoing Opportunity:

DUR Board Meeting Process: New drugs, therapeutic classes and/or supplemental rebate classes under review will be posted to the DCH website at <http://dch.georgia.gov/durb-meeting-information> approximately 30 days prior to the Manufacturers' Forum. Input specific to the drugs under review from manufacturers are made directly to NHC via GAMedicaid@nhc-llc.com and reported as appropriate by NHC at subsequent DURB meetings.

Upon review of information, and based on its expertise and discussions, the DURB makes recommendations to GDCH.

Opportunity to Appeal to GDCH:

GDCH Review Process: DURB recommendations are reviewed by GDCH for final decisions. Manufacturers may request an appeal meeting directly with GDCH after conclusion of each quarterly DURB meeting and **this appeal meeting must be conducted within 10 business days following the DURB meeting.** **Contact: Shirmary Hodges at (404) 656-4044 or shodges@dch.ga.gov**

Presentation Opportunity:

Manufacturers' Forum: A forum prior to each relevant DURB meeting whereby manufacturers may present:

- 1) Clinical information relevant to a new drug on the market under review by the DURB at the next meeting.
- 2) Clinical information relevant to ongoing NHC/OptumRx clinical management strategies (e.g. review of drug benefit plan designs, new drugs coming to market, new indications, etc.) as deemed necessary by NHC/OptumRx.

Please see the Manufacturers' Forum Announcement at

<http://dch.georgia.gov/durb-meeting-information>.

Questions not addressed in this document may be sent to NorthStar HealthCare Consulting by e-mail: GAMedicaid@nhc-llc.com

2026

Upcoming Meetings

Drug Utilization Review Board Meeting

2 Martin Luther King Jr. Drive, S.E.

Atlanta, Georgia 30334

Department of Community Health Board Room - Room 470-A
East Tower, Balcony Level

Wednesday, April 15, 2026: 10:00am – 2:00pm

Wednesday, July 15, 2026: 10:00am – 2:00pm

Wednesday, October 21, 2026*: 10:00am – 2:00pm

*Please note the October date change from the tentative schedule

Drug Utilization Review Board

Board Member	Credentials	Specialty/Area of Expertise
Gurinder J.S. Doad, Chair	M.D., Ph.D.	Family Practice
Drew A. Miller, Vice-Chair	R.Ph.	Retail Pharmacy
Douglas C. Collins	M.D.	Hematology/Oncology
Alton Condra III	R.Ph.	Inpatient Pharmacy
M. Celeste Fowler	Pharm.D., HCMBA	340B Pharmacy
Torey A. Jones	Pharm.D., MBA	340B Pharmacy
Burton L. Lesnick	M.D., FAAP	Pediatrics/Pediatric Pulmonology
Robyn Lorys	Pharm.D.	Academia - Professor
J. Russell May	Pharm.D.	Academia - Professor
Matthew Perri III	Ph.D., R.Ph.	Academia - Professor
Brent L. Rollins	R.Ph., Ph.D.	Academia - Professor
Danny A. Toth	R.Ph.	Pharmacy Benefit Plans
Suzanne M. Walton	Pharm.D., BCPS, BCOP	Hematology/Oncology
Glenda Wrenn	M.D.	Psychiatry, Academia - Professor